Doranidazole

Doranidazole (PR 350) is a radiosensitizer. Doranidazole increases the radiosensitivity of hypoxic SCCVII cells. Doranidazole significantly enhances radiation-induced growth delay in SCCVII tumors when administered intravenously before tumor irradiation. Doranidazole radiosensitizes tumors to an extent that depends on the tumor's oxygenation status. Doranidazole can be used for the study of lymphoma and hypoxic pancreatic tumors^[1][2][3]. In Vitro:Doranidazole (1 mM) significantly enhances the radiosensitivity of hypoxic SCCVII cells in vitro^[1].
Doranidazole (0.1-3.0 mM) can dose-dependently increase radiation-induced micronucleus formation in hypoxic SCCVII cells^[1].
Doranidazole (1 mM) enhances radiation-induced apoptosis in Mouse L5178Y lymphoma cells under hypoxic conditions^[2]. In Vivo:Doranidazole (50-200 mg/kg, tail vein injection, once) significantly enhances the radiosensitivity of SCCVII tumor cells in mice^[1].
Doranidazole (50-200 mg/kg, tail vein injection, once) significantly enhances radiation-induced growth delay of SCCVII tumors in mice and reduces the radiation dose required^[1].
Doranidazole (200 mg/kg, tail vein injection, once) can enhance the radiosensitization response of CFPAC-1 tumors in nude mice, but has no radiosensitizing effect on MIA PaCa-2 tumors^[1].
Doranidazole (50-200 mg/kg, tail vein injection, once) exhibits a radiosensitizing effect that correlates with tumor oxygenation status; tumors with high hypoxia (such as SCCVII and CFPAC-1) respond better, while well-oxygenated tumors (such as MIA PaCa-2) show no sensitizing effect^[1].
Doranidazole (100-250 mg/kg, i.v., once) shows a clear radiosensitizing effect on all four pancreatic cancer cell lines in xenograft nude mice, and the effect is dose-dependent^[3].